Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)PRNewsWire • 10/13/21
Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chairman Leonard MazurPRNewsWire • 10/01/21
Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021PRNewsWire • 09/14/21
Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15PRNewsWire • 09/08/21
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer IndicationsPRNewsWire • 09/07/21
Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business UpdatePRNewsWire • 08/12/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Citius Pharmaceuticals, Inc. - CTXRPRNewsWire • 07/07/21
Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming MilestonesPRNewsWire • 07/07/21
Are Options Traders Betting on a Big Move in Citius Pharmaceuticals (CTXR) Stock?Zacks Investment Research • 07/07/21
Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as PlannedPRNewsWire • 07/01/21